Triggered by a Phase I data read out for TAK-062, Takeda Pharmaceutical has exercised an option given to it as part of a 2017 agreement to acquire PvP Biologics. Looking forward, Takeda plans to advance TAK-062 through Phase IIb studies. TAK-062 joins Takeda’s other celiac disease treatment, TAK-101, which was in-licensed from Cour Pharmaceutical when Takeda exercised an option for the drug in October 2019.